行情

BPMC

BPMC

蓝图医药
NASDAQ

实时行情|Nasdaq Last Sale

59.69
-0.70
-1.16%
盘后: 59.69 0 0.00% 17:01 04/03 EDT
开盘
59.61
昨收
60.39
最高
60.98
最低
58.02
成交量
36.23万
成交额
--
52周最高
102.98
52周最低
43.29
市值
32.25亿
市盈率(TTM)
-8.1796
分时
5日
1月
3月
1年
5年

分析师评级

15位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测BPMC价格均价为104.64,最高价位130.00,最低价为70.00。

EPS

BPMC 新闻

更多
  • 欧佩克+会议推迟 沙特与俄罗斯紧张局势升级 周一油价料将暴跌
  • 新浪美股 · 1小时前
  • 迪拜将人员流动限制措施扩大至24小时限制
  • 新浪美股 · 3小时前
  • 特朗普称将申请更多中小企业纾困资金
  • 央视 · 4小时前
  • 美加联合施压促减产 考虑对沙特和俄罗斯石油征税
  • 新浪美股 · 4小时前

所属板块

生物技术和医学研究
-0.50%
制药与医学研究
-0.22%

热门股票

代码
价格
涨跌幅

BPMC 简况

Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. It focuses on crafting drug candidates that provide clinical responses to patients without adequate treatment options. It has developed a small molecule drug pipeline in cancer and a genetic disease. Its drug candidate, BLU-285, targets KIT, including Exon 17 mutations, and targets PDGFRa, including the D842V mutation. These mutations activate receptor tyrosine kinases that are drivers of cancer and proliferative disorders, including gastrointestinal stromal tumors (GIST), and systemic mastocytosis (SM). Its drug candidate BLU-554 targets FGFR4, a kinase that is activated in a defined subset of patients with hepatocellular carcinoma (HCC), the common type of liver cancer. It is engaged in developing BLU-667, a drug candidate that targets RET, a receptor tyrosine kinase that is activated by mutations or translocations.
展开

微牛提供Blueprint Medicines Corp(NASDAQ-BPMC)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的BPMC股票新闻,以帮助您做出投资决策。